Jonathan Edelman, senior vice president of CSL’s vaccines innovation unit, said the approval “marks a significant milestone” ...

Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

The European Commission has granted marketing authorization for Kostaive (ARCT-154), a self-amplifying mRNA COVID-19 vaccine, ...

The first sa-mRNA vaccine to reach any market was Gennova Biopharmaceuticals' Gemcovac, which was launched in India in 2022 ...

CSL (CSLLY) and Arcturus Therapeutics (ARCT) announced that the European Commission has granted marketing authorization for Kostaive, a ...

CSL (CSLLY) and Arcturus Therapeutics (ARCT) announced that the European Commission has granted marketing authorization for Kostaive, a ...

KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months post-vaccination compared to conventional ...

KOSTAIVE is the first sa-mRNA COVID-19 vaccine to receive approval from the European Commission. KOSTAIVE is currently marketed in Japan against COVID-19. KOSTAIVE represents a significant ...

The centralized marketing authorization of KOSTAIVE is valid in all EU member states and in the EEA countries. "The European Commission's approval marks a significant milestone in our ongoing ...